Table 1.
The role of serum calprotectin as a biomarker of IBD in different investigations
| Author | Year | Disease | Patient number | Role as biomarker |
|---|---|---|---|---|
| Kalla et al. (37) | 2016 | IBD | 35 CD, 45 UC, 3 IBDU | Disease burden, diagnosis, prognosis. |
| Hare et al.(38) | 2013 | UC | 45 | Prognosis |
| Meuwis et al.(18) | 2013 | CD | 115 | Complementary role to fecal calprotectin and hsCRP in the prediction of relapse |
| Lügering et al.(39) | 1995 | CD | 62 | Discriminating the disease relapse |
| Leach et al. (40) | 2007 | IBD | 29 CD, 4 UV, 6 IBDU | Disease burden |
| Fukunaga et al. (17) | 2018 | IBD | 41 UC, 13 CD | Warrants further validation in large cohorts. |
| McCann et al. (42) | 2017 | GI disorder | 109 | None |
IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; IBDU: inflammatory bowel disease type unclassified; hsCRP: high sensitivity C-reactive protein.